QC
CGTX icon

Quadrature Capital’s Cognition Therapeutics CGTX Stock Holding History

Quadrature Capital’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,513
Closed -$39.8K – 1437
2025
Q4 		$39.8K Sell
29,513
-233,574
-89% -$379K ﹤0.01% 1189
2025
Q3 		$358K Buy
+263,087
New +$359K ﹤0.01% 622

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Quadrature Capital's CGTX Position: Q1 2026 in Review

Quadrature Capital sold out of Cognition Therapeutics (CGTX) in Q1 2026, closing a stake of 29,513 shares — an estimated $39.8K sold.

Quadrature Capital first reported a position in CGTX in Q3 2025 and held it in 2 quarters. The position peaked at $358K in Q3 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Quadrature Capital reported no remaining Cognition Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 29,513 Cognition Therapeutics shares in Q1 2026, an estimated $39.8K.
  • Quadrature Capital first reported a position in Cognition Therapeutics in Q3 2025 and held it in 2 quarters.
  • Quadrature Capital's Cognition Therapeutics position peaked at $358K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.